Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
VRCA

VRCA - Verrica Pharmaceuticals Inc Stock Price, Fair Value and News

$6.08-0.07 (-1.14%)
Market Closed

71/100

VRCA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

71/100

VRCA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

VRCA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VRCA Price Action

Last 7 days

14.5%

Last 30 days

6.9%

Last 90 days

-23.2%

Trailing 12 Months

2.9%

VRCA RSI Chart

VRCA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VRCA Valuation

Market Cap

104.4M

Price/Earnings (Trailing)

-5.84

Price/Sales (Trailing)

2.94

Price/Free Cashflow

-5.93

VRCA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

VRCA Fundamentals

VRCA Revenue

Revenue (TTM)

35.6M

Rev. Growth (Yr)

1.4K%

Rev. Growth (Qtr)

-64.5%

VRCA Earnings

Earnings (TTM)

-17.9M

Earnings Growth (Yr)

50.17%

Earnings Growth (Qtr)

-2.8K%

VRCA Profitability

Return on Equity

-72.29%

Return on Assets

-37.95%

Free Cashflow Yield

-16.88%

VRCA Investor Care

Shares Dilution (1Y)

87.17%

Diluted EPS (TTM)

-1.67

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202515.3M23.1M30.8M35.6M
20249.5M13.9M10.7M7.6M
202307.7M6.4M5.1M
202211.3M10.5M9.8M9.0M
202100012.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About Verrica Pharmaceuticals Inc

VRCA
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing VP-315, an oncolytic peptide-based injectable therapy for the treatment of dermatology oncologic conditions, including basal cell carcinoma; and cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, including non-metastatic melanoma and non-metastatic Merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
 CEO
 WEBSITEverrica.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES22

Verrica Pharmaceuticals Inc Frequently Asked Questions

VRCA is the stock ticker symbol of Verrica Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Verrica Pharmaceuticals Inc is 104.45 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, VRCA's PE ratio (Price to Earnings) is -5.84 and Price to Sales (PS) ratio is 2.94. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VRCA PE ratio will change depending on the future growth rate expectations of investors.